Systematic Review or Meta Analysis

Nanotechnology approaches aim to improve how cytokine-targeting therapies are delivered in IBD, which could reduce systemic exposure and immunogenicity and increase local effectiveness.

This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is...

Keratoconus can threaten vision; identifying risk factors helps clinicians and patients consider prevention, early detection, and targeted eye care. Some commonly encountered issues in people with IBD—like dry eye or...

This review organizes and grades causal evidence linking individual gut bacteria, their metabolites, and host pathways in IBD—helping researchers and clinicians see which microbe–metabolite mechanisms are best supported...

People with Crohn's disease or ulcerative colitis might see more AI-based prognostic tools in the literature, but this review shows most models are not yet proven ready for clinical use because they lack key validation...

A Cochrane network meta-analysis compares many biologic medicines used for Crohn’s disease, which can help patients and clinicians understand how different drugs and drug classes stack up for inducing and keeping...

RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.

Dysplasia is the key premalignant change that raises colorectal cancer risk in people with colonic IBD. Better detection and clearer management pathways can reduce cancer risk and help patients avoid unnecessary surgery.

If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and...

People with IBD are often interested in new, less toxic therapies that restore gut health. PEVs are an emerging microbiome-based approach that could one day offer targeted immune and barrier benefits without live...

The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...

Sarcopenia or low muscle mass may be linked with worse endoscopic healing and reduced durability of biologic therapy in IBD, particularly Crohn's disease, which could matter for prognosis and treatment planning if...

This review links lactic acid bacteria ecology in engineered communities to potential applications in gut health and IBD research, which could guide future microbiome-based interventions.

This pooled analysis compares multiple microbiota-directed therapies and suggests FMT, probiotics, and synbiotics may improve clinical remission in adults with IBD, with FMT also showing benefit for endoscopic remission....

Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...

This review outlines BEVs as a microbiome-derived, engineered nanotherapy concept that could influence gut barrier repair and immune regulation—areas directly relevant to managing IBD activity and treatment resistance.

The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular...

PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...

Depression is common in people with ulcerative colitis and affects quality of life and disease outcomes. Knowing research trends helps patients and clinicians see where evidence and care approaches are focused,...

MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...

AI could help standardize endoscopic and histologic scoring in IBD, speed capsule endoscopy interpretation, and improve lesion detection — changes that might affect monitoring and diagnosis workflows for people with...

This meta-analysis pools randomized trial data and finds that FMT increased both clinical and endoscopic remission in ulcerative colitis versus placebo, which could matter to patients and clinicians exploring...

The PD‑1/PD‑L1 pathway helps suppress harmful inflammation in IBD but can later allow colorectal tumors to avoid immune attack; understanding this balance matters for patients concerned about long‑term cancer risk and...

Environmental exposures from agricultural chemicals may affect the gut microbiome and intestinal inflammation, which could be one factor influencing IBD risk or flares. Understanding these links could point to preventive...

S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...

Vitamin D may support intestinal barrier integrity and immune regulation—pathways central to mucosal healing and disease control in IBD. Understanding the evidence helps patients and clinicians consider vitamin D as a...

Microbial changes after ileocecal resection appear linked to the degree of postoperative inflammation; understanding these changes could help predict or prevent Crohn’s recurrence after surgery.

IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...

People with IBD may see growing interest in nonpharmacologic approaches like acupuncture; this review summarizes preclinical evidence suggesting acupuncture can reduce inflammation and support intestinal barrier proteins...

This study suggests that genetic risk for Crohn disease and ulcerative colitis may causally increase the risk of developing ankylosing spondylitis, an inflammatory joint condition that commonly co-occurs with IBD.

A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...

Fatigue is a common, impactful symptom in pediatric and young-adult IBD but is poorly defined and measured, limiting the ability to design age-appropriate supports. This review highlights gaps that affect patients' daily...

Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...

CDI is a common and important complication in people with IBD; which antibiotic is used can affect recurrence risk and subsequent need for surgery. This review pools available studies and suggests vancomycin may reduce...

The review connects molecular cell-cycle changes to the progression from chronic IBD to colorectal cancer, pointing to pathways and cell-cycle regulators that could become prevention or treatment targets for...

A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...

This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.

Depressive symptoms are common in IBD and can worsen quality of life and disease management; non-drug options that may improve mood are especially relevant for patients seeking adjunctive or accessible therapies.

People with IBD may be interested because the review identifies polysaccharides from traditional Chinese medicine as a potential source of new therapies that act on gut microbes, the intestinal barrier, and immune...

RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.

Sleep disturbance is common in IBD and may relate to disease risk and flares. Understanding which sleep problems are linked to onset or activity could point to new ways to support people with IBD.

The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.

This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...

Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.

TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis and Research and clinical trials. The original article is from Cochrane Database of Systematic...

Environmental pollutants that are increasing in many East Asian settings — air pollution, heavy metals, pesticides, and microplastics — may contribute to rising IBD rates by affecting the gut microbiome and intestinal...

Metformin is a common, inexpensive drug with possible anti-inflammatory effects; this review compiles preclinical and early clinical data suggesting it might influence ulcerative colitis biology. Readers may want to know...